Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE.

Minimed Group (MMED) recently came onto investors’ radar after a sharp 8.4% one day share price move. This has prompted a closer look at how its diabetes focused medical technology business and current financial profile fit into portfolios.

See our latest analysis for Minimed Group.

That sharp 1 day move sits within a softer recent trend, with a 1 day share price return of 8.42% decline and a year to date share price return of 10.60% decline from the current US$16.53 level. This suggests that sentiment has cooled rather than accelerated.

If Minimed’s volatility has you looking beyond a single name, this could be a good moment to scan our screener of 34 healthcare AI stocks as potential alternatives in the broader theme.

With the shares under pressure and Minimed still loss making on US$2,886.0m of revenue, is the current price overlooking long term potential, or are investors already factoring in any future growth?

Preferred Price-to-Sales of 1.6x: Is It Justified?

At a last close of $16.53, Minimed Group is trading on a P/S of 1.6x, which sits below both its peer group and the broader US medical equipment industry.

The P/S ratio compares the company’s market value to its revenue, which can be useful when earnings are negative, as they are here with a reported loss of $211.0m on $2,886.0m of revenue. For a business that is still loss making, investors often look at what they are paying for each dollar of current sales while they wait to see whether those sales eventually translate into profits.

What stands out is that Minimed’s 1.6x P/S is described as good value relative to the US Medical Equipment industry average of 2.8x, and also versus a peer average of 2.2x. That is a clear discount, which suggests the market is pricing Minimed’s revenue less generously than comparable medical technology names, even though its revenue grew by 11.4% over the past year.

See what the numbers say about this price — find out in our valuation breakdown.

Result: Price-to-Sales of 1.6x (UNDERVALUED)

However, the company is still loss making on US$2,886.0m of revenue and remains a subsidiary of Medtronic, which could influence future strategic flexibility.

Find out about the key risks to this Minimed Group narrative.

Next Steps

Given this mix of cooling sentiment and potential value signals, it makes sense to move quickly and review the underlying data yourself. To see how the current concerns and positives stack up side by side, take a look at 1 key reward and 2 important warning signs .